GlassScriptPhysician profile
Kevin Swiatek
NPI 1982022901
$1,679.33
in general payments reported to CMS, 2019-2025
13 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.24 · 2022: $374 · 2023: $381 · 2024: $236 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $22.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.54 |
| Education | $22.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $472.33 | 2022-2024 | Yupelri, Tobi Podhaler |
| Insmed, INC. | $261.66 | 2022-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $236.85 | 2019-2025 | Breztri, Symbicort, Tagrisso |
| Verona Pharma, INC. | $189.74 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $121.52 | 2025 | Tobi Podhaler |
| Glaxosmithkline, LLC. | $107.53 | 2022-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.93 | 2023-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Boston Scientific Corporation | $44.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.25 | 2024 | Glassia |
| Harmony Biosciences LLC | $35.34 | 2023 | Wakix |
| Genzyme Corporation | $34.18 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $28.83 | 2025 | Uptravi, Opsynvi |
| Vertex Pharmaceuticals Incorporated | $25.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Swiatek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.